WASHINGTON — In a stunning development that defies both medical science and basic economics, the Food and Drug Administration yesterday announced it would consider a patient’s ability to pay before approving certain cancer treatments. The new policy, titled ‘Patient Financial Readiness Assessment Framework,’ reportedly will evaluate not just a drug’s safety and efficacy, but also whether the patient has sufficient income to afford it before it can be prescribed.

‘This is a transformative step in healthcare equity,’ FDA Commissioner Robert Califf told a packed room at the agency’s headquarters. ‘No longer will we approve treatments that patients simply cannot access. Now, if you can’t afford your medicine, we won’t approve it for you. It’s not that we’re denying access — it’s that we’re requiring upfront financial clearance.’

The framework comes after a series of ‘patient affordability audits’ revealed that 62% of cancer patients would be uninsured by the time their treatment arrived. The FDA says this shocking statistic — discovered during what it calls the ‘Patient Payment Capacity Investigation’ — justified the new approval standards.

Under the new rules, patients must submit income verification, proof of insurance coverage, and a signed affidavit stating they can cover out-of-pocket costs before the FDA will even review their drug application. This comes after the agency’s ‘Drug Accessibility Impact Statement’ determined that 73% of approved treatments failed to meet the new ‘affordability threshold.’

Dr. Emily Chen, a leading patient advocacy attorney, said she’s concerned about the new standards. ‘This is the exact opposite of what patients need,’ she said. ‘If you can’t afford the medicine, that’s a systemic problem we should solve with policy, not regulatory bureaucracy. Now the FDA is essentially saying, if you’re too poor, we won’t approve your treatment.’

The FDA’s new approach has drawn criticism from industry groups, patient advocacy organizations, and even some lawmakers. Representative Maria Santos, a Democrat from New Jersey, said the policy reflects a troubling trend toward bureaucratic overreach. ‘Instead of solving the root problem — which is that we’re spending too much of our health budget on bureaucracy — we’re just adding more requirements to an already broken system.’

The FDA says it’s not stopping patients from getting care. ‘We’re just ensuring that treatments go to people who can afford them,’ Califf said. ‘If you can’t pay, you won’t get the approval. That’s not discrimination — it’s fiscal responsibility.’

The FDA’s new policy also requires drugmakers to provide payment plan options for approved treatments. Under the ‘Drug Affordability Guarantee Act,’ companies must offer installment payment plans, income-based pricing, and direct manufacturer subsidies. This comes after the agency’s ‘Price Transparency and Accessibility Review’ found that 44% of patients couldn’t afford their prescriptions despite approval.

The FDA’s new policy has already caused confusion in clinical trial settings, where researchers are scrambling to figure out how to apply the new standards. Some hospitals say they’re turning away trial participants because they can’t meet the new financial requirements. Others say they’re creating separate approval tracks for different patient populations.

The FDA’s new policy has also triggered a wave of regulatory changes in other agencies. The Department of Health and Human Services has announced it will review ‘financial eligibility’ for all Medicare-covered treatments. The Centers for Medicare and Medicaid Services has also launched a new ‘Patient Affordability Initiative’ that will require providers to prove patients can afford treatments before prescribing them.

‘This is exactly the kind of regulation that makes healthcare more expensive and less accessible,’ Santos said. ‘We’re just adding more requirements to an already broken system.’